CN110402251A - 枯草杆菌酶细胞毒素b亚基突变体 - Google Patents

枯草杆菌酶细胞毒素b亚基突变体 Download PDF

Info

Publication number
CN110402251A
CN110402251A CN201780082403.7A CN201780082403A CN110402251A CN 110402251 A CN110402251 A CN 110402251A CN 201780082403 A CN201780082403 A CN 201780082403A CN 110402251 A CN110402251 A CN 110402251A
Authority
CN
China
Prior art keywords
linked
acid
glycolylneuraminic acid
protein
glycolylneuraminic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780082403.7A
Other languages
English (en)
Chinese (zh)
Inventor
M·P·詹宁斯
C·达伊
A·W·佩顿
J·C·佩顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Griffith University
Adelaide University
Original Assignee
University of Adelaide
Griffith University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016904572A external-priority patent/AU2016904572A0/en
Application filed by University of Adelaide, Griffith University filed Critical University of Adelaide
Publication of CN110402251A publication Critical patent/CN110402251A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21062—Subtilisin (3.4.21.62)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201780082403.7A 2016-11-09 2017-11-09 枯草杆菌酶细胞毒素b亚基突变体 Pending CN110402251A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016904572 2016-11-09
AU2016904572A AU2016904572A0 (en) 2016-11-09 Subtilase cytotoxin b subunit mutant
PCT/AU2017/051230 WO2018085888A1 (en) 2016-11-09 2017-11-09 Subtilase cytotoxin b subunit mutant

Publications (1)

Publication Number Publication Date
CN110402251A true CN110402251A (zh) 2019-11-01

Family

ID=62109062

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780082403.7A Pending CN110402251A (zh) 2016-11-09 2017-11-09 枯草杆菌酶细胞毒素b亚基突变体

Country Status (9)

Country Link
US (2) US11371033B2 (https=)
EP (1) EP3538544B1 (https=)
JP (1) JP7123921B2 (https=)
KR (1) KR102703633B1 (https=)
CN (1) CN110402251A (https=)
AU (1) AU2017358401B2 (https=)
CA (1) CA3044303A1 (https=)
ES (1) ES2983352T3 (https=)
WO (1) WO2018085888A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112760305B (zh) * 2021-01-25 2022-04-29 浙江工业大学 一种栖热腔菌磷酸酶突变体及其应用
EP4334722A4 (en) * 2021-05-06 2025-03-19 Inoviq Inc. METHODS RELATING TO TUMOR-DERIVED EXTRACELLULAR VESICLES
US20240239846A1 (en) * 2021-05-14 2024-07-18 The University Of Adelaide Methods of analysing a sample

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050136424A1 (en) * 2003-12-22 2005-06-23 Paton Adrienne W. Cytotoxin with a subtilase domain
WO2012101235A1 (en) * 2011-01-26 2012-08-02 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO007396A0 (en) 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
ATE292144T1 (de) 2002-08-02 2005-04-15 Inst Curie Shiga-toxin-untereinheit b als vektor zur diagnose von tumoren und zur arzneimittelverabreichung an gb3-exprimierenden tumoren

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050136424A1 (en) * 2003-12-22 2005-06-23 Paton Adrienne W. Cytotoxin with a subtilase domain
WO2012101235A1 (en) * 2011-01-26 2012-08-02 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ADRIENNE W. PATON等: "A New Family of Potent AB5 Cytotoxins Produced by Shiga Toxigenic Escherichia coli", 《THE JOURNAL OF EXPERIMENTAL MEDICINE》 *

Also Published As

Publication number Publication date
AU2017358401B2 (en) 2022-01-13
WO2018085888A1 (en) 2018-05-17
JP2020501521A (ja) 2020-01-23
AU2017358401A1 (en) 2019-05-30
EP3538544A4 (en) 2020-04-15
JP7123921B2 (ja) 2022-08-23
EP3538544B1 (en) 2024-03-27
KR20190084995A (ko) 2019-07-17
KR102703633B1 (ko) 2024-09-05
US20190367895A1 (en) 2019-12-05
US11371033B2 (en) 2022-06-28
CA3044303A1 (en) 2018-05-17
EP3538544A1 (en) 2019-09-18
US20220372459A1 (en) 2022-11-24
ES2983352T3 (es) 2024-10-22

Similar Documents

Publication Publication Date Title
JP7479435B2 (ja) 癌治療および判断ターゲットとしてのｌｙ７５
JP5945381B2 (ja) タンパク質
KR102167550B1 (ko) Dll3 결합 시약을 포함하는 암에 대한 치료적 및 진단적 타겟
KR101523705B1 (ko) Ｓｐａｒｃ 결합 ｓｃｆｖｓ
EP3322715B1 (en) Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof
EP2680004B1 (en) Methods for detecting cancer
JP2006517911A (ja) Ｇｐｒ６４に対する抗体とその利用法
KR20170002500A (ko) 항muc1 항체 또는 그의 항원 결합성 단편 및 그 용도
JP6588893B2 (ja) 卵巣がんの自己抗体バイオマーカー
US20220372459A1 (en) Subtilase cytotoxin b subunit mutant
JP2011509079A (ja) エフリンａ型受容体１０タンパク質
JP6113721B2 (ja) 治療標的及び診断標的
US20110305630A1 (en) Misfolded proteins in cancer treatment and diagnosis
JP2012511894A (ja) Ｐｔａ０７２タンパク質
KR20150131655A (ko) Aimp2-dx2-34s 단백질 및 이의 제조방법
HK40000286A (en) Gene products differentially expressed in tumors and their uses
HK40000286B (en) Gene products differentially expressed in tumors and their uses
WO2000052470A1 (fr) Moyen de diagnostic et de traitement de la leucemie

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination